Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Similar articles for PubMed (Select 17233922)

1.

Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression.

Wang Z, Lecane PS, Thiemann P, Fan Q, Cortez C, Ma X, Tonev D, Miles D, Naumovski L, Miller RA, Magda D, Cho DG, Sessler JL, Pike BL, Yeligar SM, Karaman MW, Hacia JG.

Mol Cancer. 2007 Jan 19;6:9.

2.

Tumor localization and antitumor efficacy of novel sapphyrin compounds.

Naumovski L, Sirisawad M, Lecane P, Chen J, Ramos J, Wang Z, Cortez C, Magda D, Thiemann P, Boswell G, Miles D, Cho DG, Sessler JL, Miller R.

Mol Cancer Ther. 2006 Nov;5(11):2798-805.

3.

Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.

Naumovski L, Ramos J, Sirisawad M, Chen J, Thiemann P, Lecane P, Magda D, Wang Z, Cortez C, Boswell G, Gyu Cho D, Sessler J, Miller R.

Mol Cancer Ther. 2005 Jun;4(6):968-76.

4.

Novel 2-step synthetic indole compound 1,1,3-tri(3-indolyl)cyclohexane inhibits cancer cell growth in lung cancer cells and xenograft models.

Lee CH, Yao CF, Huang SM, Ko S, Tan YH, Lee-Chen GJ, Wang YC.

Cancer. 2008 Aug 15;113(4):815-25. doi: 10.1002/cncr.23619.

6.

New two-photon activated photodynamic therapy sensitizers induce xenograft tumor regressions after near-IR laser treatment through the body of the host mouse.

Starkey JR, Rebane AK, Drobizhev MA, Meng F, Gong A, Elliott A, McInnerney K, Spangler CW.

Clin Cancer Res. 2008 Oct 15;14(20):6564-73. doi: 10.1158/1078-0432.CCR-07-4162.

7.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.

Eguchi T, Itadani H, Shimomura T, Kawanishi N, Hirai H, Kotani H.

Mol Cancer Ther. 2009 Jun;8(6):1460-72. doi: 10.1158/1535-7163.MCT-08-1159. Epub 2009 Jun 9.

8.

[Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].

Zhou YL, Hu WX, Lü YP, Qiu LN, Wang WS, Yang ZY, Liu JD, Rao GW.

Yao Xue Xue Bao. 2007 Jan;42(1):26-34. Chinese.

PMID:
17520803
9.

Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen.

Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ Jr.

Cancer Res. 2008 Jan 15;68(2):415-24. doi: 10.1158/0008-5472.CAN-07-2120.

10.

Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment.

Schwartz DR, Moin K, Yao B, Matrisian LM, Coussens LM, Bugge TH, Fingleton B, Acuff HB, Sinnamon M, Nassar H, Platts AE, Krawetz SA, Linebaugh BE, Sloane BF.

Mol Cancer Res. 2007 May;5(5):443-54.

11.

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M.

Mol Cancer Ther. 2008 Oct;7(10):3275-84. doi: 10.1158/1535-7163.MCT-08-0508.

12.
13.

Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.

Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, Magda D.

Cancer Res. 2005 Dec 15;65(24):11676-88.

14.

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

Magda D, Lecane P, Miller RA, Lepp C, Miles D, Mesfin M, Biaglow JE, Ho VV, Chawannakul D, Nagpal S, Karaman MW, Hacia JG.

Cancer Res. 2005 May 1;65(9):3837-45.

15.

Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S.

Int J Mol Med. 2009 Jul;24(1):45-50.

PMID:
19513533
16.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
17.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

18.

Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells.

Buytaert E, Matroule JY, Durinck S, Close P, Kocanova S, Vandenheede JR, de Witte PA, Piette J, Agostinis P.

Oncogene. 2008 Mar 20;27(13):1916-29. Epub 2007 Oct 22.

PMID:
17952126
19.

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.

Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.

Breast Cancer Res Treat. 2009 Sep;117(1):45-54. doi: 10.1007/s10549-008-0163-6. Epub 2008 Sep 13.

PMID:
18791823
20.

Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.

Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J, Airley R.

Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93. Epub 2007 May 23.

PMID:
17520257
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk